Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Mark P. Foster"'
Autor:
Xiao Ma, Marina Bakhtina, Irina Shulgina, William A Cantara, Alexandra B Kuzmishin Nagy, Yuki Goto, Hiroaki Suga, Mark P Foster, Karin Musier-Forsyth
Publikováno v:
Nucleic Acids Research. 51:3988-3999
High fidelity tRNA aminoacylation by aminoacyl-tRNA synthetases is essential for cell viability. ProXp-ala is a trans-editing protein that is present in all three domains of life and is responsible for hydrolyzing mischarged Ala-tRNAPro and preventin
Autor:
Hong-Duc Phan, Andrew S Norris, Chen Du, Kye Stachowski, Bela H Khairunisa, Vaishnavi Sidharthan, Biswarup Mukhopadhyay, Mark P Foster, Vicki H Wysocki, Venkat Gopalan
Publikováno v:
Nucleic Acids Research. 50:8154-8167
RNase P is a ribonucleoprotein (RNP) that catalyzes removal of the 5 ' leader from precursor tRNAs in all domains of life. A recent cryo-EM study of Methanocaldococcus jannaschii (Mja) RNase P produced a model at 4.6-angstrom resolution in a dimeric
Autor:
Arnaud P. J. Giese, Wei-Hsiang Weng, Katie S Kindt, Vanessa H. H. Chang, Jonathan S Montgomery, Evan M. Ratzan, Alisha J. Beirl, Roberto Aponte Rivera, Jeffrey M. Lotthammer, Sanket Walujkar, Mark P. Foster, Omid A. Zobeiri, Jeffrey R. Holt, Saima Riazuddin, Kathleen E. Cullen, Marcos Sotomayor, Zubair M Ahmed
Publikováno v:
bioRxiv
Calcium and integrin-binding protein 2 (CIB2) and CIB3 bind to transmembrane channel-like 1 (TMC1) and TMC2, the pore-forming subunits of the inner-ear mechano-electrical transduction (MET) apparatus. Whether these interactions are functionally relev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34a43260b3faad82ecf004cd3b46a544
https://europepmc.org/articles/PMC10312449/
https://europepmc.org/articles/PMC10312449/
Autor:
Mikhail Tarasov, Heather L. Struckman, Yusuf Olgar, Alec Miller, Mustafa Demirtas, Vladimir Bogdanov, Radmila Terentyeva, Andrew M. Soltisz, Xiaolei Meng, Dennison Min, Galina Sakuta, Izabella Dunlap, Antonia D. Duran, Mark P. Foster, Jonathan P. Davis, Dmitry Terentyev, Sándor Györke, Rengasayee Veeraraghavan, Przemysław B. Radwański
Publikováno v:
Journal of Clinical Investigation. 133
Autor:
Nancy L. Bartlett, Felicia Gomez, Matthew Mosior, Malachi Griffith, Anne Fischer, Michelle Becker-Hapak, Mark P. Foster, Melissa M. Berrien-Elliott, Alina D. Schmidt, Marcus Watkins, Amanda F. Cashen, Kilannin Krysiak, Kami J. Maddocks, Nina D. Wagner-Johnston, Jingqin Luo, Obi L. Griffith, Zachary L. Skidmore, Todd A. Fehniger, Sweta Desai, Jeffrey P. Ward
Publikováno v:
Blood
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor therapy. The CD30-targeted, antibody-drug
Autor:
Ethan McClain, Sweta Desai, Amanda F. Cashen, Mark P. Foster, Peter Westervelt, Patrick Soon-Shiong, Michelle Becker-Hapak, Keith Stockerl-Goldstein, Jeffrey S. Miller, Miriam T. Jacobs, Mark A. Schroeder, Pamela Wong, Camille N. Abboud, Patrick Pence, Geoffrey L. Uy, Feng Gao, Claudio G. Brunstein, Melissa M. Berrien-Elliott, Meagan A. Jacoby, Iskra Pusic, Sarah Cooley, John F. DiPersio, Todd A. Fehniger
Publikováno v:
Blood. 139:1177-1183
Natural killer (NK) cells are a promising alternative to T cells for cancer immunotherapy. Adoptive therapies with allogeneic, cytokine-activated NK cells are being investigated in clinical trials. However, the optimal cytokine support after adoptive
Publikováno v:
Biophysical Journal. 122:40a-41a
Autor:
Pamela Wong, Jin-An Jiao, Timothy Schappe, Gilles M. Leclerc, Sweta Desai, Gabriela J. Muniz, Melissa M. Berrien-Elliott, Mark P. Foster, Lynne Marsala, Pallavi Chaturvedi, Carly Neal, Niraj Shrestha, Christian A. Echeverri, Xiaoyun Zhu, David A. Russler-Germain, Caitlin A. Prendes, Catherine M. Spanoudis, Todd A. Fehniger, Ethan McClain, Jack O. Egan, Michael J. Dee, Peter R. Rhode, Hing C. Wong, Jennifer Tran, Laritza L. Ramirez, Ryan P. Sullivan, Lijing You, Victor L. Gallo, Julia A. Wagner, Emily K. Jeng, Michelle Becker-Hapak, Patrick Pence
Publikováno v:
Cancer Immunol Res
Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-15, and rhIL
Publikováno v:
Hand Surgery & Rehabilitation
This work aimed to identify the lead causes of upper limb injury presenting to a busy hand and major trauma unit during the UK COVID-19 domestic lockdown period, in comparison to a cohort from the same period one year previously. Hand and upper limb
Autor:
Amanda F. Cashen, Matthew L. Cooper, Carly Neal, Camille N. Abboud, Feng Gao, Sweta Desai, Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Celia C. Cubitt, Timothy Schappe, Pamela Wong, Mark A. Schroeder, John F. DiPersio, Peter Westervelt, Julia A. Wagner, Jennifer A. Foltz, Meagan A. Jacoby, Natalia Jaeger, Iskra Pusic, Mark P. Foster, Geoffrey L. Uy, Todd A. Fehniger, Ethan McClain, Rizwan Romee, Keith Stockerl-Goldstein, Sridhar Nonavinkere Srivatsan
Publikováno v:
Cancer Discov
Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with acute myeloid leukemia (AML). However,